Abstract 32P
Background
Worldwide breast cancer morbidity and mortality was still positioned in the top. Epidemiological data for breast cancer in Bali was not available although is essential for planning health measures. This study aimed to summarise the demographics of breast cancer subjects in Sanglah Genral Hospital from 2012-2019 and emphasize variables that related.
Methods
This is a descriptive study, collecting all breast cancer subjects data from January 2012 to 2019. All data from the cancer registry were analyzed and tabulated. Data were described as count and percentages. Reasoning analysis was done by looking at the counts from year to year. Information for counting age standardized rate was taken in national census data of population in Bali. Literature review if articles were also screened for the filtering out of the data regarding epidemiology of breast cancer in worldwide for comparison.
Results
A total of 1627 cases from 2012 to 2019 were included in this study for analysis. The incidence of breast cancer increase from 187 cases to 364 cases from 2013 to 2016. The age-standardized incidence rate was 84.33 per 100.000 women Balinese population. Most cases were found in advanced stages, stage IIIB (29.38%) and stage IV (22.56%). The most common tumor status found was T4 (49.78%), N1 (41.49%), and 22.5% were found to have metastasis. Lung metastasis dominated all the metastasis cases with the rate of 42.35%. Majority of histopathology subtypes in breast cancer subjects were invasive carcinoma of non special type (NST) (78.8%), followed by invasive lobular carcinoma (12.4%). From 1627 subjects, only 1160 (71.3%) had subtype tested, with luminal B subtype dominated the cases (36.5%).
Conclusions
Geographical and phenotypical variations differ from breast cancer subject epidemiology. Thus, statistical data should be done in each region for a better diagnosis and treatment care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract